Micafungin

Summary

Micafungin is an approved echinocandin antifungal given by intravenous infusion for the treatment and prophylaxis of invasive fungal infections, especially those caused by Candida and Aspergillus species. It is a cyclic lipopeptide marketed under names such as Mycamine and is used in immunocompromised patients where serious, life‑threatening infections require potent therapy.

Mechanism of Action

Micafungin inhibits the fungal enzyme β‑1,3‑D‑glucan synthase, a key catalyst in cell‑wall biosynthesis. Blocking production of β‑1,3‑D‑glucan weakens the cell wall, causing osmotic instability and fungal cell death. Mutations in the FKS1 and FKS2 genes, which encode subunits of this synthase, reduce drug binding and underlie echinocandin resistance.

What the Research Shows

Recent literature provides several insights into micafungin use. A 2020 review of antimicrobial dosing during continuous renal replacement therapy (CRRT) includes micafungin among agents requiring updated dosing strategies, highlighting limited specific guidance for this drug. Clinical safety reviews note that echinocandins, including micafungin, can cause hepatic enzyme elevations, although severe hepatotoxicity is uncommon. Pharmacokinetic analyses describe micafungin’s hepatic enzymatic metabolism, independent of cytochrome P450 pathways, resulting in a relatively low potential for drug‑drug interactions compared with azoles. Resistance mechanisms have been mapped to FKS1/FKS2 mutations that diminish β‑1,3‑D‑glucan synthase binding. Nephrotoxicity appears minimal, with expert opinion ranking echinocandins as having a much lower renal risk than amphotericin B formulations.

Reported Benefits

Clinical experience shows micafungin provides effective coverage against Candida and Aspergillus infections, with a favorable safety profile that includes low nephrotoxicity and limited drug‑drug interactions due to its non‑CYP metabolism. Its intravenous route ensures reliable systemic exposure, useful in critically ill patients who cannot tolerate oral agents.

Limitations of the Evidence

Evidence for optimal dosing in special populations such as those undergoing CRRT remains sparse, and dosing recommendations are largely extrapolated from limited studies. Hepatic adverse effects, while generally mild, have been reported, and emergence of resistance via FKS mutations can compromise efficacy. No oral formulation exists, restricting use to settings where IV access is feasible.

Safety Considerations

Micafungin is generally well tolerated; the most common safety signals involve transient elevations in liver enzymes, with rare cases of clinically significant hepatitis. Renal toxicity is uncommon. Because the drug is metabolised enzymatically in the liver without involvement of cytochrome P450 enzymes, it has a lower propensity for drug‑drug interactions, but caution is advised in patients with pre‑existing hepatic impairment. Monitoring of liver function tests is recommended during therapy.

How It Is Administered

Micafungin is supplied as micafungin sodium for intravenous infusion. It is administered by slow IV push or infusion, typically once daily, in a sterile solution. No oral or other routes are approved.

Routes of Administration

Goals & Uses

• Disseminated candidiasisTherapeuticHigh
• Treatment of invasive aspergillosisAntifungalLow
• Pediatric candidal infectionsAntifungal TreatmentModerate
• Prophylaxis in hematopoietic stem cell transplantationPreventiveHigh
• Invasive candidiasis treatmentAntifungalHigh
• Treatment of candidemia and invasive candidiasisAntifungal TreatmentHigh
• Prophylaxis of Candida infections in HSCT recipientsAntifungal ProphylaxisHigh
• Treatment of esophageal candidiasisAntifungal TherapyHigh
• Esophageal candidiasisTherapeuticHigh
• Febrile neutropenia with suspected fungal infectionTherapeuticModerate

Contraindications

• Severe hepatic impairment (Child-Pugh C)HepaticModerate
• Hypersensitivity to micafungin or other echinocandinsAllergyHigh
• Neonates <4 monthsAgeModerate
• Known hypersensitivity to micafungin or other echinocandinsAllergyHigh
• Severe hepatic impairment (relative)Organ ImpairmentModerate

Adverse Effects

• Phlebitis/infusion site reactionsLocal/infusionUncommon
• Elevated liver enzymes (AST/ALT)HepatotoxicityCommon
• RashDermatologicUncommonSkin eruption or discoloration
• HeadacheNeurologicUncommonPain in the head or upper neck
• Anaphylaxis/hypersensitivityImmunologicRare
• Infusion-related reactions (e.g., flushing, pruritus)GeneralCommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Elevated liver transaminasesHepaticCommon
• Hemolytic anemiaHematologicRare

Drug Interactions

• RifampinModerate
• Oral contraceptivesLowDelayed gastric emptying may affect absorption timing
• ItraconazoleLow
• CyclosporineModerate
• NifedipineLow
• Amphotericin B deoxycholateModerate
• SirolimusModerate

Population Constraints

• Pregnancy (Category C)ReproductiveRelative
• Pediatric patients (≥4 months)AgeRelative
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Neonates/premature infantsPediatricRelative
• Patients with hepatic impairmentOrgan FunctionRelative
• BreastfeedingReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Invasive candidiasis, Esophageal candidiasis, Prophylaxis in hematopoietic stem cell transplantationEMA approval 2005
• United StatesApprovedApproved: Invasive candidiasis, Esophageal candidiasis, Prophylaxis in hematopoietic stem cell transplantationApproved 2005
• United KingdomApprovedApproved: Invasive candidiasis, Esophageal candidiasis, Prophylaxis in hematopoietic stem cell transplantationMHRA approved

FDA approved in 2005; EU EMA approved 2005; contraindicated in patients with hypersensitivity; pediatric use limited.

Evidence & Sources

• Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy
  Journal ArticleModerateLi L, et al.2020-01-01T00:00:00.000000Z
• Clinical hepatotoxicity associated with antifungal agents
  Journal ArticleModerateKyriakidis I, et al.2017-01-01T00:00:00.000000Z
• Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
  Journal ArticleModerateBellmann R, Smuszkiewicz P2017-01-01T00:00:00.000000Z
• Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
  Journal ArticleModerateCzajka KM, et al.2023-01-01T00:00:00.000000Z
• Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions
  Journal ArticleModerateTragiannidis A, et al.2021-01-01T00:00:00.000000Z

Frequently Asked Questions